FDA Panel Blesses Otsuka’s Hyponatremia Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Oral therapy jumps efficacy-but-no-clinical-benefit hurdle.
You may also be interested in...
Cornerstone’s Hyponatremia Therapy Lixivaptan Will Get Advisory Panel Scrutiny
The hyponatremia drug is a selective vasopressin V2-receptor antagonist, like Astellas’ Vaprisol and Otsuka’s Samsca.
Defining Efficacy Without Proof Of Benefit: FDA Panel To Assess Otsuka’s Samska
Cardio-Renal Advisory Committee meets June 25 to review tolvaptan’s effect on serum sodium in hyponatremia.
FDA Accepts NDA For Otsuka’s Novel Hyponatremia Treatment
Tolvaptan could be the first oral vasopressin receptor antagonist on the market.